Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpuraLinus A. Völker, H Felten, Thomas Osterholt et al.|Journal of Thrombosis and Haemostasis|2023Cited by 50
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchangeLucas Kühne, Paul Brinkkötter, Paul Knöbl et al.|Blood|2024Cited by 31
Management of Immune Thrombotic Thrombocytopenic Purpura Without Therapeutic Plasma ExchangeLucas Kühne, Paul T. Brinkkoetter, Paul Knoebl et al.|SSRN Electronic Journal|2023Cited by 1